Brief: Nurix Therapeutics Receives Prime Designation From The European Medicines Agency For NX-5948
20/11/2024 21:58
Nov 20 (Reuters) - Nurix Therapeutics Inc NRIX.O :
* NURIX THERAPEUTICS RECEIVES PRIME DESIGNATION FROM THE
EUROPEAN
MEDICINES AGENCY FOR NX-5948 FOR THE TREATMENT OF RELAPSED OR
REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Source text: ID:nGNX8N5qWQ
Further company coverage: NRIX.O
Recent news on Nurix Therapeutics
See all newsNurix Therapeutics Q3 swings to profit on Roche collaboration
Brief: Nurix Extends Gilead Collaboration For Oncology Program
Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis